Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment
Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as well as entailing large economic costs.
The III Northern Headache Meeting will start next Friday 7th June, a two-day conference with expert speakers in the field of headaches who will discuss the latest advances in their diagnosis and treatment.
The meeting is organised by Julio Pascual and Vicente González, researchers from the Clinical and Genetic Group of Headaches at the Marqués de Valdecilla Health Research Institute (IDIVAL) and neurologists from the Marqués de Valdecilla University Hospital (HUMV) and is sponsored by Lundbeck, Pfizer, Almirall, abbvie, Teva and Lilly-Organon.
The conference will take place at the Hotel Santemar in Santander and registration can be done through the following link: https://forms.gle/kWNyBDqaz2ataFTu5
In the first session, after the opening and welcome by the organisers, there will be a round table discussion entitled “Not everything is migraine” in which researchers Gabriel Gárate and Jorge Madera will discuss the biomarkers that currently exist to diagnose migraine, as well as the different types of headaches and how to differentiate them.
This will be followed by a competition of clinical cases presented by people who are doing their residency in medicine (MIR) in the speciality of neurology and the last year of their internship in hospitals in Castilla y León, Asturias, the Basque Country, Navarre, La Rioja or Cantabria. Cases may be submitted until 30 May to the following address: v.glezquintanilla@gmail.com.
For the selection of the winning case, on the one hand, the evaluation by the Scientific Committee will take into account aspects such as the description, the systematics of the diagnosis, the review of the literature, the interest and the innovation. On the other hand, the participants will have to present their case orally and those attending the conference will be able to score them. Finally, the average of the scores of the jury and the audience will be calculated and the winner will receive a prize. In addition, those clinical cases with a score of at least 5 out of 10 will be collected in a digital book with ISBN.
The second session of the conference, on 8 June, will consist of two round tables focusing on the field of migraine, such as the current treatment of symptoms and new drugs under study such as monoclonal antibodies or new oral gepants. Finally, the indications and controversies of neuroimaging techniques in headaches will be discussed and there will be a final colloquium on the future of a headache consultation.
You can download the programme with detailed rules for participating in the clinical case competition here:
Programme III Northern Headache Meeting 2024 and clinical cases
Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as […]
Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment
Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as well as entailing large economic costs.
The III Northern Headache Meeting will start next Friday 7th June, a two-day conference with expert speakers in the field of headaches who will discuss the latest advances in their diagnosis and treatment.
The meeting is organised by Julio Pascual and Vicente González, researchers from the Clinical and Genetic Group of Headaches at the Marqués de Valdecilla Health Research Institute (IDIVAL) and neurologists from the Marqués de Valdecilla University Hospital (HUMV) and is sponsored by Lundbeck, Pfizer, Almirall, abbvie, Teva and Lilly-Organon.
The conference will take place at the Hotel Santemar in Santander and registration can be done through the following link: https://forms.gle/kWNyBDqaz2ataFTu5
In the first session, after the opening and welcome by the organisers, there will be a round table discussion entitled “Not everything is migraine” in which researchers Gabriel Gárate and Jorge Madera will discuss the biomarkers that currently exist to diagnose migraine, as well as the different types of headaches and how to differentiate them.
This will be followed by a competition of clinical cases presented by people who are doing their residency in medicine (MIR) in the speciality of neurology and the last year of their internship in hospitals in Castilla y León, Asturias, the Basque Country, Navarre, La Rioja or Cantabria. Cases may be submitted until 30 May to the following address: v.glezquintanilla@gmail.com.
For the selection of the winning case, on the one hand, the evaluation by the Scientific Committee will take into account aspects such as the description, the systematics of the diagnosis, the review of the literature, the interest and the innovation. On the other hand, the participants will have to present their case orally and those attending the conference will be able to score them. Finally, the average of the scores of the jury and the audience will be calculated and the winner will receive a prize. In addition, those clinical cases with a score of at least 5 out of 10 will be collected in a digital book with ISBN.
The second session of the conference, on 8 June, will consist of two round tables focusing on the field of migraine, such as the current treatment of symptoms and new drugs under study such as monoclonal antibodies or new oral gepants. Finally, the indications and controversies of neuroimaging techniques in headaches will be discussed and there will be a final colloquium on the future of a headache consultation.
You can download the programme with detailed rules for participating in the clinical case competition here:
Programme III Northern Headache Meeting 2024 and clinical cases
Speakers who are experts in the field of headaches will discuss the latest advances in their diagnosis and treatment Headaches, characterised by recurrent headaches, are one of the most common disorders of the nervous system, affecting people of all ages, races, income levels and geographical areas. It is not only painful but also disabling, as […]
Cohorte IMPaCT is an ambitious health study of the Instituto de Salud Carlos III coordinated by the Centro de Investigación Biomédica en Red (CIBER) that aims to monitor the health of 200,000 people living in Spain over 20 years.
Cohorte IMPaCT is being developed thanks to the participation of all the Autonomous Communities. It will be carried out in 50 primary care health centers (IMPaCT Centers) belonging to the health services of the 17 Autonomous Communities and Ceuta and Melilla, where recruitment, information collection and periodic contact with the participants will be carried out.
IMPaCT Cohort in Cantabria
One of these 50 IMPaCT Centers will be located in Cantabria. The Puertochico Health Center, where the IMPaCT Center is located, has a multidisciplinary team made up of researchers and healthcare professionals from the Cantabrian Health Service. Users of the Puertochico Health Center, CS Isabel II and CS Dávila of Santander will be called from this Health Center.
In Cantabria, the IMPaCT Cohort is managed by the Valdecilla Research Institute (IDIVAL) and the Cantabrian Health Service, through the Primary Care Management, coordinates and executes the study in the Puertochico Health Center (Santander) as the project node. Cohorte IMPaCT is coordinated in Cantabria by Luis Mariano López López, Director of Nursing at the Marqués de Valdecilla University Hospital, and Álvaro Ramos Acosta, Deputy Director of Nursing at the Marqués de Valdecilla University Hospital.
A representative sample of the Spanish population
The IMPaCT Cohort has been designed so that its 200,000 participants are a representative sample of the Spanish population. Territorially, there are IMPaCT Centers in all the Autonomous Communities and in Ceuta and Melilla. In line with the distribution of the Spanish population, 30% of these centers will be in rural areas and another 70% in urban areas.
A person cannot volunteer to participate in the IMPaCT Cohort. To ensure a faithful representation of the Spanish population, participants are chosen at random. Persons aged 16 to 79 years living in Spain with public health coverage and whose care is provided by Public Health Service centers will be eligible.
Cohorte IMPaCT will mark the history of science in our country: a project of everyone and for everyone that will allow us to better understand why some people get sick and others do not. This project will help us to improve the health of future generations in Spain.
People who have been selected will receive a text message telling them that they will be contacted from their Health Center to participate in the study, as well as a link to the project’s informative website. The involvement of the citizens who are called to participate is key to the success of the project, which is why its slogan is: “If they call you, come!
Video presentation of IMPaCT Cohort in Cantabria:
IMPaCT Cohort Web Page
Cohorte IMPaCT is an ambitious health study of the Instituto de Salud Carlos III coordinated by the Centro de Investigación Biomédica en Red (CIBER) that aims to monitor the health of 200,000 people living in Spain over 20 years. Cohorte IMPaCT is being developed thanks to the participation of all the Autonomous Communities. It will […]
The event will take place on May 21 at IDIVAL’s facilities
The Marqués de Valdecilla Health Research Institute (IDIVAL) is organizing a round table discussion entitled “Artificial intelligence: how can we use it in the healthcare environment” on May 21.
The initiative will take place in person at the IDIVAL headquarters at 13:30h and will last one hour. It will also be available in streaming through the zoom platform.
It will be aimed at anyone interested in the subject, especially researchers, clinical and management staff.
Manuel Desco, Professor of Radiology in the Department of Bioengineering at the Carlos III University of Madrid, Director of the Innovation Support Unit at the Gregorio Marañón Research Institute; Julio Mayol, Professor of Surgery at the Complutense University of Madrid and Director of the Innovation Support Unit at the San Carlos Health Research Institute and, finally, Joaquín Cayón, Head of the Legal Service of the Ministry of Health of Cantabria and IDIVAL researcher, will share their vision at the round table. The moderator of the round table will be Galo Peralta, Director of Management of IDIVAL.
Registration for the conference can be made through the following link:
https://forms.gle/bW5LsqMg2RR6PKTNA
Certificates of attendance will be awarded.
The event will take place on May 21 at IDIVAL’s facilities The Marqués de Valdecilla Health Research Institute (IDIVAL) is organizing a round table discussion entitled “Artificial intelligence: how can we use it in the healthcare environment” on May 21. The initiative will take place in person at the IDIVAL headquarters at 13:30h and will […]
Promoting patient safety culture is the aim of the conference organized by the Cantabrian Service on May 15 and 16 at HUMV
On May 15 and 16, the XIV Conference on Quality and Patient Safety will be held, an activity organized by the Subdirectorate of Care, Training and Continuity of Care of the Cantabrian Health Service (SCS) and sponsored by Johnson and Johnson, Gilead, Pfizer, Roche and AstraZeneca.
The conference will take place at the Dr. Gómez Durán conference room of the Marqués de Valdecilla University Hospital (HUMV) from 4pm to 8pm and is aimed at all professionals, patients, relatives and anyone interested in patient quality and safety.
Registration is now open until May 9, 2024 and can be done online through SOFOS Moodle in the case of SCS professionals or through the following form for external professionals:
https://www.scsa[1]lud.es/web/forms/shared/-/form/28746751
The program of the event includes several round tables focused on examples of innovations that generate value, on the purposes to ensure quality and patient safety, on projects developed to address infection from all angles and also on proposals carried out by patients. They intend to be an open and participatory discussion forum giving visibility to the projects, activities and experiences developed by healthcare professionals in this field.
In order to obtain the course diploma, it is necessary to attend 100% of the course, as well as to fill in the evaluation survey on the training activity.
Audio and/or video recordings may be made, in whole or in part, based on the training objectives of the workshop and for its dissemination. In addition, accreditation has been requested from the Commission of Continuing Education of the health professions of Cantabria for students previously enrolled in the conference.
Download program:
Jornada seguridad del paciente 2024 _tríptico
Promoting patient safety culture is the aim of the conference organized by the Cantabrian Service on May 15 and 16 at HUMV On May 15 and 16, the XIV Conference on Quality and Patient Safety will be held, an activity organized by the Subdirectorate of Care, Training and Continuity of Care of the Cantabrian Health […]
Projects can be submitted in two categories until June 30.
The Marqués de Valdecilla Health Research Institute (IDIVAL), in collaboration with the Nursing Department of the “Marqués de Valdecilla” University Hospital (HUMV) has published the rules of the 26th National Call for Research Projects “Nursing Valdecilla”.
The aim of this call, funded by the Caja Cantabria Foundation, is to encourage the participation of nursing professionals in the elaboration and development of research projects.
Applications can be submitted until June 30, 2024 through this link on the IDIVAL website and for any questions you can contact proyectos2@idival.org.
There are 2 categories:
-Best project, endowed with 4,000 €.
-Best Project to be developed at the Marqués de Valdecilla University Hospital (HUMV), with 2,000 €.
Requirements
Characteristics of the projects
Research projects on nursing practice in any of its aspects are the object of this call. They will have a maximum duration of two years and the aid granted may totally or partially finance the project.
In the case of projects lasting more than one year, the continuity of the aid for the second year will be subject to the evaluation of the Annual Report, presented within the deadline and correctly documented.
Documentation required
The documentation shall be submitted according to standardized models, available on the aid platform within the IDIVAL website and is as follows:
(a) Standardized application form signed by the PI of the project, which shall include:
– Personal data of the PI
– Report of the research project including the sections indicated in the standardized model.
– Composition of the research team
The absence of any of these documents implies the non-acceptance of the project for its evaluation.
Projects can be submitted in two categories until June 30. The Marqués de Valdecilla Health Research Institute (IDIVAL), in collaboration with the Nursing Department of the “Marqués de Valdecilla” University Hospital (HUMV) has published the rules of the 26th National Call for Research Projects “Nursing Valdecilla”. The aim of this call, funded by the Caja […]
This advisory body meets regularly and ensures the scientific quality of the institute.
The members of the External Scientific Council of the Marqués de Valdecilla Health Research Institute (IDIVAL) met last week at IDIVAL and online in order to evaluate the activity of some research groups of the center, as well as to monitor the Strategic Plan 2022-2026.
For the evaluation, the principal investigators (PIs) of each group gave a fifteen-minute presentation followed by a 30-minute discussion with the members of the board.
The groups evaluated at this meeting were the Nanomedicine Group; the Hematological Neoplasms and Hematopoietic Progenitor Transplantation Group; the Medical Oncology Group and the Neurodegenerative Diseases Group.
Likewise, the advance of the 2023 report was presented, which reflects the most relevant information of the institute for the past year in terms of scientific production, patronage or the program for the promotion of research, among others.
The External Scientific Council ensures the scientific quality of the institute
The External Scientific Council is a consultative body in charge of advising on IDIVAL’s scientific activities, as well as ensuring its scientific quality as indicated in the Statutes and in IDIVAL’s Rules of Organization and Operation.
It is made up of experts in the field of health sciences of recognized prestige in the scientific community and is appointed by the Board of Trustees at the proposal of the scientific management of IDIVAL. It is chaired by Ángel Carracedo Álvarez, Professor of Legal Medicine at the University of Santiago de Compostela and has ten members:
This advisory body meets regularly and ensures the scientific quality of the institute. The members of the External Scientific Council of the Marqués de Valdecilla Health Research Institute (IDIVAL) met last week at IDIVAL and online in order to evaluate the activity of some research groups of the center, as well as to monitor the […]
The conclusions obtained in the research could help design policies to address the difficulties of this type of families.
A recent study published in the international Journal of Family and Economic Issues by the Health Economics Group of the Marqués de Valdecilla Health Research Institute (IDIVAL) explored economic circumstances, lifestyle factors (obesity, smoking and alcohol) and social support among single-parent families in Europe.
In 2019, Europe had 3.2% of single-parent families out of all households, a relatively high rate that has led researchers and policymakers to understand its economic and demographic situation. The study conducted by IDIVAL has analysed a total of 20 European countries through microdata from the European Health Interview Survey (EHIS).
The main findings indicate that both single mothers and fathers face more pressing economic challenges compared to their partnered counterparts, suggesting that lower levels of education, reduced income and poor economic conditions are common among single parents.
Also, single parents have poorer physical health compared to cohabiting couples. These results suggest that single parenthood can have a negative impact on general health, and that such special difficulties require further support, especially when we consider that three quarters of such households are headed by women.
On the other hand, social support relationships also differ between single and partnered individuals. In this case, they experience less supportive relationships compared to cohabiting couples.
Thus, this study provides valuable information for designing community-based interventions to mitigate the adverse effects of lone parenthood for both parents and their children. It is essential to address these inequalities and ensure adequate supports for lone parents.
Reference: Paloma Lanza-León & David Cantarero-Prieto. The Loud Silent Side of Single Parenthood in Europe: Health and Socio-Economic Circumstances from a Gender Perspective. Journal of Family and Economic Issues, 18 de abril de 2024.
The conclusions obtained in the research could help design policies to address the difficulties of this type of families. A recent study published in the international Journal of Family and Economic Issues by the Health Economics Group of the Marqués de Valdecilla Health Research Institute (IDIVAL) explored economic circumstances, lifestyle factors (obesity, smoking and alcohol) […]
1.7 million, the project will run until the end of 2025 and will involve leading international institutions in the sector.
The FAITHFUL, innovation project consortium, led by the Spanish startup Idoven, thanks to the support of EIT Health, has just launched the development of a technological solution that aims to prevent 4 out of 10 hospitalisations due to heart failure (HF) in Europe.
With funding of 1.7 million euros, the project will run until the end of 2025, involving leading international institutions in the sector. Cantabria participates in this project through the Cardiovascular Research Group of the Valdecilla Research Institute (IDIVAL) and the Cardiology Service of the Marqués de Valdecilla University Hospital (HUMV) together with the Primary Care Management.
The project is based on the use of advanced algorithms and artificial intelligence applied to electrocardiograms to detect early signs of heart failure in primary care. By providing a disease score from electrocardiogram results, this innovative approach provides clinicians at health centres with crucial information to make informed decisions on patient treatment and management, and can refer patients to cardiologists earlier.
The project will recruit more than 2,500 European patients with risk factors associated with heart failure to demonstrate the reliability of its algorithm in the early detection of heart failure decompensation.
Given the enormous social and healthcare burden of heart failure, early detection will have a positive impact on the quantity and quality of life of patients and on the consumption of system resources.
FAITHFUL has been selected by EIT Health in its Flagships call which aims to boost the development and adoption of digital health solutions, maximise the potential of health data, adopt new value-based healthcare models, and strengthen the European healthcare industry.
Under the leadership of Idoven, the FAITHFUL consortium consists of AstraZeneca Spain, the Madrid Health Service (SERMAS), the Foundation for Biomedical Research of the Hospital 12 de Octubre, the Foundation for Biomedical Research of the Hospital Gregorio Marañón, the Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria, the Institut Català de la Salut, Karolinska Institute, Region Stockholm, MADoPA – Centre Expert en Technologies et Services pour le Maintien en Autonomie à Domicile des Personnes Âgées and the Estonian Health Insurance Fund. In addition, FAITHFUL has the collaboration of several key external partners including IDIVAL, the Fundacio TIC Salut Social and the Fundación del Ilustre Colegio Oficial de Médicos de Madrid (Fundación ICOMEM).
Heart failure leads the way in hospital admissions
Heart failure affects 770,000 people in Spain1 and more than 15 million in Europe2. 2 It is also the leading cause of hospitalisation in people over 65 years of age and of unscheduled hospital readmissions3. Studies suggest that hospitalisations for HF will increase by 50% in the next 25 years4, mainly due to the progressive ageing of the population and a growing prevalence of cardiovascular risk factors such as hypertension, diabetes, hypercholesterolemia and obesity, among others.
Dr Manuel Marina Breysse, cardiologist and CEO of Idoven, explains: “This project has the potential to radically transform the way heart failure is diagnosed and managed. Heart failure represents a huge cost to healthcare systems because it is difficult to diagnose before it manifests itself. “In this way, we want to contribute to the sustainability of the healthcare system, improving the health and quality of life of the population,” adds Dr Marina Breysse.
“This project represents our dedication to the forefront of cardiovascular health,
highlighting the crucial role of digital health innovation and artificial intelligence in redefining the future of healthcare. As Core partners of EIT Health, we are co-leading the drive for the transformation of healthcare systems in Spain, fostering an approach that integrates effectiveness, efficiency and profoundly patient-centric care,” says AstraZeneca Spain’s Director of Innovation and Digital Strategy, Dr. César Velasco.
As Dr Izabel Alfany, CEO of EIT Health Spain, explains, “We promote collaborative leadership among all our partners and ecosystem actors to make transformative innovation in Spain and Europe possible. We support the FAITHFUL project and the organisations that make up its consortium because they help us to lead the culture of innovation in Spain and because they will enable a significant improvement in the healthcare and health of heart failure patients”.
References
(1) Sicras-Mainar, A., Sicras-Navarro, A., Palacios, B., Varela, L., & Delgado, J. F. (2020). Epidemiología y tratamiento de la insuficiencia cardiaca en España: estudio PATHWAYS-HF. Revista Española de Cardiología. Published. https://doi.org/10.1016/j.recesp.2020.09.014
(2) Heart Failure Policy Network. Heart Failure Policy and Practice in Europe. London: HFPN; 2020. Available at: http://www.healthpolicypartnership.com/app/uploads/Heart-failure-policy-and-practice-in-Europe.pdf
(3) ¿Qué es la insuficiencia cardíaca? (2021, 8 febrero). Heart Failure Matters. https://www.heartfailurematters.org/es/ conocer-la-insuficiencia-cardiaca/que-es-la-insuficiencia-cardiaca/
(4) Cowie, M. R., Anker, S. D., Cleland, J. G. F., Felker, G. M., Filippatos, G., Jaarsma, T., Jourdain, P., Knight, E., Massie, B., Ponikowski, P., & López-Sendón, J. (2014). Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Failure, 1(2), 110–145. https://doi. org/10.1002/ehf2.12021
1.7 million, the project will run until the end of 2025 and will involve leading international institutions in the sector. The FAITHFUL, innovation project consortium, led by the Spanish startup Idoven, thanks to the support of EIT Health, has just launched the development of a technological solution that aims to prevent 4 out of 10 […]
Registrations for the DTEC-VAL programme are open until 10 May.
The Valdecilla Health Research Institute (IDIVAL) is once again launching the DTEC-VAL programme to support the Development of Health Technologies, a call for applications as part of the Programme of Aid for the Promotion of Biosanitary Research (PLADIBIO).
The aim of the DTEC-VAL programme is to promote innovation in general and specifically to support the development of health technologies in our environment through the funding of late-stage innovation projects that facilitate collaboration between the health sector, the university environment and companies.
Applications can be made until 10 May via this link on the IDIVAL website and any queries related to the procedures and the project can be sent to the email address proyectos2@idival.org
The duration of the projects will be 1 year and the maximum amount to be granted per project is €20,000. The funding granted may finance all or part of the project.
Project requirements
In general, newly developed projects that show potential for transfer to the National Health System will be considered eligible. Projects may also be partially developed at university and in companies.
The thematic scope includes the areas of Biomedicine, Electromedicine, Pharmaceutical Technologies, Health Technologies and Sciences, as well as Biotechnology, Chemical Technology and Materials applied to human health and Information and Communication Technologies applied to health and health, as well as any others related to innovation in health systems.
Innovation projects must be developed mainly in the public health environment of Cantabria and must be aimed at innovation and development in the health field. The project must have a previous protected development or in the protection phase in which an institution of the Public Health System of Cantabria participates in at least 50%, at TRL 3 or higher.
Documentation required
Together with the application, the following documents must be submitted
Registrations for the DTEC-VAL programme are open until 10 May. The Valdecilla Health Research Institute (IDIVAL) is once again launching the DTEC-VAL programme to support the Development of Health Technologies, a call for applications as part of the Programme of Aid for the Promotion of Biosanitary Research (PLADIBIO). The aim of the DTEC-VAL programme is […]
